Sichuan Goldstone Asia Pharmaceutical Inc
SZSE:300434
Relative Value
The Relative Value of one Sichuan Goldstone Asia Pharmaceutical Inc stock under the Base Case scenario is hidden CNY. Compared to the current market price of 10.77 CNY, Sichuan Goldstone Asia Pharmaceutical Inc is hidden .
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
Competitors Multiples
Sichuan Goldstone Asia Pharmaceutical Inc Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
S
|
Sichuan Goldstone Asia Pharmaceutical Inc
SZSE:300434
|
4.3B CNY | 4.1 | 33.2 | 25 | 25 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
987B USD | 15.1 | 47.8 | 32.2 | 34.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
592.7B USD | 6.3 | 22.1 | 15.3 | 18.9 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
298.4B CHF | 4.9 | 31.7 | 13.3 | 15.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.8B GBP | 5.5 | 31.8 | 17.5 | 24.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
248.3B CHF | 5.7 | 22.8 | 14 | 18.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
309B USD | 4.8 | 16.9 | 10.6 | 12.4 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.5 | 10.7 | 7.9 | 9.3 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.4B USD | 2.5 | 19.9 | 7.4 | 9.9 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
124.1B USD | 2.6 | 17.6 | 7.4 | 9.1 |